Until mid-March, the therapeutic landscape of NASH<\/a> lacked the FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments<\/strong> like diet and exercise. Supplemental interventions encompassed off-label<\/strong> usage of vitamin E<\/strong> and antidiabetic agents<\/strong> (e.g., pioglitazone, liraglutide) and liver transplantation in the case of most severe cases. Given NASH\u2019s multifaceted pathogenesis, effective treatment demands comprehensive targeting of various cellular and molecular pathways.<\/p>\n\n\n\n Recently, in March 2024, Madrigal Pharmaceuticals\u2019 groundbreaking product, REZDIFFRA<\/strong> (resmetirom)<\/a>, a once-daily, oral THR-\u03b2 agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole <\/strong>FDA-sanctioned therapy for adults afflicted with non-cirrhotic NASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2\u2013F3 fibrosis. Set to debut in April 2024, this milestone heralds a new era of hope and progress for individuals grappling with NASH, promising to revolutionize treatment paradigms with its integration alongside diet and exercise regimens. The accelerated green light for REZDIFFRA stands as a pivotal moment in the annals of NASH therapeutics, igniting fresh vigor and impetus within the NASH community.\u00a0<\/p>\n\n\n\n Additionally in Europe, the marketing authorization application for REZDIFFRA is currently under review by the European Medicines Agency Committee for Medicinal Products for Human Use.<\/p>\n\n\n\n Based on the robust efficacy and safety data generated in two large Phase III MAESTRO studies<\/strong>, it is believed that REZDIFFRA will become the foundational therapy for patients with NASH with moderate to advanced liver fibrosis. Also now that the FDA has approved REZDIFFRA for NASH<\/a>, pharmaceutical companies will have a better understanding of the thresholds they must meet to get future approvals.<\/p>\n\n\n\n Physicians hope the REZDIFFRA\u2019s approval \u201cenergizes\u201d the field and leads to more treatment advances. Madrigal Pharmaceuticals has already garnered widespread support among physicians. A significant portion of gastroenterologists plan to incorporate the brand into their practice within six months of its launch<\/strong>. They estimate that over a third of their patients with MASH\/NASH could benefit from the drug, suggesting rapid adoption and utilization. Physicians are hopeful that insurance providers will cover the cost of REZDIFFRA and are poised to offer it to eligible NASH patients<\/a> once it becomes available.<\/p>\n\n\n\n REZDIFFRA is available to patients with moderate to advanced fibrosis (F2\/F3) in the US from the second week of April<\/strong>, the drug is distributed through a limited specialty pharmacy network with an annual WAC of USD 47,400<\/strong>. The price reflects value as the first-and-only therapy for NASH<\/a>. Madrigal extends its unwavering commitment through the innovative Madrigal Patient Support program, facilitating insurance navigation, affordability solutions, and copay assistance for eligible recipients. Furthermore, a dedicated Patient Assistance Program (PAP) ensures access for uninsured patients seeking REZDIFFRA\u2019s transformative benefits.<\/p>\n\n\n\n In April 2024, <\/strong>Madrigal Pharmaceuticals, Inc. announced that REZDIFFRA (resmetirom)<\/strong> had become available in the U.S<\/strong>. REZDIFFRA was indicated for use alongside diet and exercise in treating adults with noncirrhotic NASH and moderate to advanced liver fibrosis (stages F2 to F3 fibrosis). Continued approval for this indication was to be contingent upon the verification and description of clinical benefit in ongoing confirmatory trials.<\/p>\n\n\n\n Bill Sibold, Chief Executive Officer of Madrigal, stated, \u201cThe introduction of REZDIFFRA as the first and only FDA-approved therapy in NASH marks a turning point for Madrigal and the NASH community. Since approval, we have been partnering with healthcare providers, payers, and patient advocates to build new care pathways that will help patients access REZDIFFRA and achieve their treatment goals. Our field teams are fully deployed, our specialty pharmacy network is processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving Rezdiffra.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n Various pharmaceutical companies have spent millions of dollars trying to develop a possible medicine, but none other than Madrigal Pharmaceuticals has been able to provide authorized treatments in the NASH treatment market<\/a>. In the latest research and development space of NASH, FXR agonists, FGF21 stimulants, FGF19 analog, glucagon-like peptide-1 (GLP-1) agonists, peroxisome proliferator-activated receptor (PPAR) regulators, THR-\u03b2 agonists,<\/strong> and some others are the most highlighted class of emerging therapies of this indication.<\/p>\n\n\n\n According to our projections, REZDIFFRA stands unchallenged as the primary treatment for NASH patients in stages F2-F3, with no foreseeable competitors shortly. Despite being the inaugural therapy approved in the US for NASH, Madrigal’s window of first-mover advantage is expected to narrow swiftly due to an increasingly crowded therapeutic environment driven by substantial unmet medical demand. It may face competition from both GLP-1 and non-GLP-1 drug candidates in development for NASH. Given the massive market size of NASH, it is not surprising that there are many (non-GLP-1) NASH drug candidates in development<\/a>. Some of these include lanifibranor (Inventiva Pharma), MSDC-0602K (Cirius Therapeutics, Inc.), Aramchol (Galmed Research and Development, Ltd.), Belapectin (Galectin Therapeutics Inc.), VK2809 (Viking Therapeutics), and others.<\/strong><\/p>\n\n\n\n![\"Rezdiffra-Roadmap\"](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/04170231\/Rezdiffra-Roadmap-1024x244.png\")
<\/figure>\n\n\n\n\n
![\"Nonalcoholic](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/04173852\/Nonalcoholic-Steatohepatitis-Market-Banner-1024x194.png\")
<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"